Growing NGS Demand CD Genomics has recently launched several NGS focused platforms and services, including Next-Generation Sequencing and refined RNA sequencing capabilities, indicating increasing demand from customers for advanced sequencing workflows across research, pharmaceutical, and academia.

Expanded Service Portfolio The company has broadened offerings to include total RNA sequencing, dual RNA-seq, oxBS-seq methylation analysis, ribosome profiling, and full-length amplicon sequencing, creating cross-sell opportunities for customers needing end-to-end transcriptomics, epigenomics, and microbiome analyses.

Global Reach With services spanning over 50 countries, CD Genomics demonstrates international demand and potential for regional partnerships, co-development pilots, and channel partnerships to accelerate market penetration in new geographic areas.

Industry Partnerships Longstanding engagement with pharmaceutical, biotech, academia, and government sectors suggests strong potential to upsell high-value genomics projects, including large-scale sequencing, genotyping, and library construction services for drug development and translational research.

Revenue Growth Signals The current revenue range and ongoing platform modernization imply room for scale through multi-service bundles, enterprise-level pricing for large projects, and expanded bioinformatics support to improve data analysis offerings for customers.